BBB seminar: Charalampos Tzoulis
NAD replenishment therapy in Parkinson’s disease: A New Hope?
Hovedinnhold
Charalampos Tzoulis
Department of Clinical Medicine, University of Bergen
Parkinson’s disease (PD) is a major cause of death and disability, with a rapidly growing global socioeconomic impact. Current treatments for PD make no substantial impact on disease progression and, despite several candidate neuroprotective therapies showing encouraging preclinical results, these have failed to show disease-modifying effects in clinical trials. A growing body of evidence suggests that therapies targeting mitochondria and NAD metabolism may confer neuroprotective effects in PD. This presentation will cover hallmark experimental evidence supporting these hypotheses, and illustrate how basic laboratory research led to the first clinical trial of NAD replenishment therapy in PD, which showed encouraging results (Cell Metabolism, Brakedal et al., doi: 10.1016/j.cmet.2022.02.001).
Neuromics research group: https://neuromics.org
Neuro-SysMed Center: https://neuro-sysmed.no
Chairperson: Aurora Martinez, Dept. of Biomedicine
